NeoGenomics, Inc. (NEO) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $9.12: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 7.74; Below-average business quality; Below long-term trend.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical... Read more
Sell if holding. Engine safety override at $9.12: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 7.74; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 68. Score 5.7/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, earnings proximity 89d clear, semi cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -13.3%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.12: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 7.74; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 68. Prior stop was $8.49. Score 5.7/10, moderate confidence.
Take-profit target: $12.02 (+31.7% upside). Prior stop was $8.49. Stop-loss: $8.49.
Quality below floor (3.4 < 4.0).
NeoGenomics, Inc. trades at a P/E of N/A (forward 27.7). TrendMatrix value score: 8.4/10. Verdict: Sell.
18 analysts cover NEO with a consensus score of 3.6/5. Average price target: $14.
What does NeoGenomics, Inc. do?NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United...
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.